Patheon plans additional investment in Milton Park, UK unit
Leading provider of contract development and commercial manufacturing services company Patheon Inc has planned to make additional investment in its Milton Park facility. Patheon is a dedicated pharmaceutical development services facility focused on early development projects.
The company currently provides proof-of-concept and first –in man development programs for oral dose forms. It also offers Quick to Clinic which provides clinical trial materials as fast as four months from receipt of active pharmaceutical ingredient.
The service has been structured to provide support to emerging pharmaceutical companies’ with promising molecules. With the first phase of additional investment to Patheon’s Milton Park facility, the company will be able to expand on the early development capabilities currently being offered, including the introduction of the SoluPath program.
The purchase of the new HME screening tool and spray-drier will supplement existing technologies at Milton Park to provide the SoluPath™ service to emerging pharmaceutical companies with poorly soluble molecules.
Robin Platt, Senior Director, Operations for Milton Park, said, “The introduction of Solupath™ into Milton Park’s existing capabilities is an exciting addition to Patheon’s service offering in Europe.” said Robin Platt, Senior Director, Operations for Milton Park.
Patheon Inc is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a wide range of solid and sterile dosage forms. It provides highest quality products and services to 300 of the world’s leading pharmaceutical and biotechnology companies.
